3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
6
Head & Neck
3
Gastrointestinal
2
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Keratosis, Actinic
23
Skin Neoplasms
7
Melanoma
7
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Squamous Cell
4
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Basal Cell
2
Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Basal Cell
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sezary Syndrome
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Squamous Cell
1
Interventions
Cyclophosphamide
16
pembrolizumab
14
Radiosurgery
7
Nivolumab
5
Celecoxib
5
poly ICLC
4
Radiation
4
Injections
4
Radiotherapy
3
Melphalan
3
Ipilimumab
3
Filgrastim
3
Etoposide
3
Docetaxel
3
Cryosurgery
3
Blood Specimen Collection
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Transurethral Resection of Prostate
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Fluorouracil
×
Dermatologic
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts